{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:27:37Z","timestamp":1793730457779,"version":"4.6.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40265-023-01885-6","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T06:02:31Z","timestamp":1684994551000},"page":"825-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Zavegepant: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"11","key":"1885_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","unstructured":"GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954\u201376.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1885_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, et al. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol. 2022;21(3):284\u201394.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1885_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40259-022-00530-0","volume":"36","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, Silberstein SD. Calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs. 2022;36(3):341\u201358.","journal-title":"BioDrugs"},{"key":"1885_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/biomedicines11020569","volume":"11","author":"A Nisar","year":"2023","unstructured":"Nisar A, Ahmed Z, Yuan H. Novel therapeutic targets for migraine. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11020569.","journal-title":"Biomedicines"},{"key":"1885_CR5","unstructured":"US FDA. NDA approval. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/216386Orig1s000ltr.pdf. Accessed 28 Mar 2023."},{"key":"1885_CR6","unstructured":"Pfizer Labs. ZAVZPRET\u2122 (zavegepant) nasal spray: US prescribing information. 2023. https:\/\/zavzpret.pfizerpro.com\/. Accessed 28 Mar 2023."},{"key":"1885_CR7","unstructured":"Biohaven Pharmaceutical Holding Company Ltd, Royalty Pharma. Biohaven and Royalty Pharma announce Royalty funding and stock purchase agreements totaling $150 million [media release]. 18 Jun 2018. https:\/\/www.prnewswire.com."},{"key":"1885_CR8","unstructured":"Biohaven Pharmaceutical Holding Company Ltd, Bristol-Myers Squibb Company. License agreement between Biohaven Pharmaceutical Holding Company Ltd. and Bristol-Myers Squibb Company. 2016. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1689813\/000104746917002426\/a2231694zex-10_1.htm. Accessed 28 Mar 2023."},{"key":"1885_CR9","unstructured":"Biohaven Pharmaceutical Holding Company Ltd. Form K-10. 2020. https:\/\/otp.tools.investis.com\/clients\/us\/biohaven_pharmaceutical\/SEC\/sec-show.aspx?FilingId=15607718&Cik=0001689813&Type=PDF&hasPdf=1. Accessed 29 Mar 2023."},{"key":"1885_CR10","unstructured":"Biohaven Pharmaceutical Holding Company. Biohaven restructures license agreement with Bristol-Myers Squibb to reduce royalties payable on its migraine product candidates; transaction financed through private placement with leading institutional investors [media release]. 12 Mar 2018. https:\/\/www.prnewswire.com."},{"key":"1885_CR11","unstructured":"Biohaven Pharmaceutical Holding C. Biohaven and Pfizer enter strategic collaboration for the commercialization of rimegepant outside the United States [media release]. 9 Nov 2021. https:\/\/www.pfizer.com."},{"key":"1885_CR12","unstructured":"Biohaven P. Biohaven and Pfizer complete collaboration transaction for commercialization of rimegepant and zavegepant outside the United States [media release]. 5 Jan 2022. https:\/\/www.pfizer.com."},{"key":"1885_CR13","unstructured":"Pfizer, Biohaven P. Pfizer completes acquisition of Biohaven Pharmaceuticals [media release]. 3 Oct 2022. https:\/\/www.pfizer.com."},{"issue":"11","key":"1885_CR14","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1016\/j.bmcl.2013.04.012","volume":"23","author":"PV Chaturvedula","year":"2013","unstructured":"Chaturvedula PV, Mercer SE, Pin SS, et al. Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery. Bioorg Med Chem Lett. 2013;23(11):3157\u201361.","journal-title":"Bioorg Med Chem Lett"},{"issue":"S1","key":"1885_CR15","first-page":"105","volume":"62","author":"R Bertz","year":"2022","unstructured":"Bertz R, Stringfellow J, Bhardwaj R, et al. Concentration QT interval modeling of intranasally administered zavegepant in healthy subjects shows absence of QT prolongation [abstract no. P-117]. Headache. 2022;62(S1):105\u20136.","journal-title":"Headache"},{"key":"1885_CR16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/head.14259","volume":"62","author":"R Bertz","year":"2022","unstructured":"Bertz R, Donohue MK, Madonia J, et al. Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults [abstract no. P-142]. Headache. 2022;62:122.","journal-title":"Headache"},{"issue":"1","key":"1885_CR17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/03331024211033829","volume":"42","author":"CM Comisar","year":"2022","unstructured":"Comisar CM, Francis J, Bhardwaj R, et al. Pharmacometric analysis of zavegepant for treatment of migraine [abstract no. MTIS22-PO-007]. Cephalalgia. 2022;42(1):53\u20134.","journal-title":"Cephalalgia"},{"issue":"S1","key":"1885_CR18","first-page":"101","volume":"62","author":"R Bhardwaj","year":"2022","unstructured":"Bhardwaj R, Donohue MK, Stringfellow J, et al. Absorption, distribution, metabolism, and elimination of 5 mg [14C]-zavegepant in healthy male subjects after a single intravenous infusion dose [abstract no. P-112]. Headache. 2022;62(S1):101\u20132.","journal-title":"Headache"},{"issue":"1 Suppl","key":"1885_CR19","first-page":"92","volume":"42","author":"R Bhardwaj","year":"2022","unstructured":"Bhardwaj R, Donohue M, Madonia J, et al. Pharmacokinetics of zavegepant nasal spray 10 mg in subjects with moderate hepatic impairment [abstract no. MTIS22-PO-053]. Cephalalgia. 2022;42(1 Suppl):92\u20133.","journal-title":"Cephalalgia"},{"issue":"1 Suppl","key":"1885_CR20","first-page":"94","volume":"42","author":"RBA Malatesta","year":"2022","unstructured":"Malatesta RBA, Stringfellow J, Madonia J, et al. Phase 1 study to evaluate the effects of rifampin on the pharmacokinetics of oral zavegepant [abstract no. MTIS22-PO-055]. Cephalalgia. 2022;42(1 Suppl):94\u20135.","journal-title":"Cephalalgia"},{"issue":"S1","key":"1885_CR21","first-page":"140","volume":"62","author":"R Bhardwaj","year":"2022","unstructured":"Bhardwaj R, Malatesta JK, Stringfellow J, et al. Effects of the strong CYP3A4 and P-glycoprotein inhibitor itraconazole on the pharmacokinetics of oral and intranasal zavegepant [abstract no. P-163]. Headache. 2022;62(S1):140\u20131.","journal-title":"Headache"},{"issue":"1 Suppl","key":"1885_CR22","first-page":"79","volume":"42","author":"R Bhardwaj","year":"2022","unstructured":"Bhardwaj R, Collins J, Madonia J, et al. Effects of multiple-dose administration of zavegepant nasal spray on the single-dose pharmacokinetics of ethinyl estradiol- levonorgestrel [abstract no. MTIS22-PO-036]. Cephalalgia. 2022;42(1 Suppl):79\u201380.","journal-title":"Cephalalgia"},{"issue":"S1","key":"1885_CR23","first-page":"108","volume":"62","author":"R Bertz","year":"2022","unstructured":"Bertz R, Bhardwaj R, Donohue MK, et al. Effects of zavegepant and concomitant sumatriptan on blood pressure and pharmacokinetics in healthy adult participants [abstract no. P-122]. Headache. 2022;62(S1):108\u20139.","journal-title":"Headache"},{"issue":"3","key":"1885_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209\u201317.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1885_CR25","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","volume":"62","author":"R Croop","year":"2022","unstructured":"Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022;62(9):1153\u201363.","journal-title":"Headache"},{"issue":"Suppl 1","key":"1885_CR26","first-page":"59","volume":"23","author":"R Croop","year":"2022","unstructured":"Croop R, Madonia J, Hould J, et al. A phase 2\/3 open-label, long-term, safety trial of zavegepant 10 mg nasal spray for the acute treatment of migraine [abstract no. P104]. J Headache Pain. 2022;23(Suppl 1):59.","journal-title":"J Headache Pain"}],"updated-by":[{"DOI":"10.1007\/s40265-023-01915-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01885-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01885-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01885-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T02:09:11Z","timestamp":1687918151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01885-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1885"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01885-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"25 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-023-01915-3","URL":"https:\/\/doi.org\/10.1007\/s40265-023-01915-3","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}